Drugs / Meta10-EGFRvIII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07244666 | Nov 2025 → Dec 2027 expected | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meta10-EGFRvIII | “Patients will receive a single infusion of Meta10-EGFRvIII.” NCT07244666 ↗ |
| Modality | Cell therapy | “metabolically armed EGFRvIII CAR-T cell injection” NCT07244666 ↗ |